Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
Clinical trial NCT03433313 · COMPLETED
Trial details
- NCT number
- NCT03433313
- Sponsor
- EirGenix, Inc.
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-16
- Primary completion
- 2022-01-20
- Enrollment
- 807
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.